Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
br Introduction Mammalian proteases comprise both the peptid
2019-09-02
Introduction Mammalian proteases comprise both the peptidases or exopeptidases, which act at the N- or C-terminal positions of polypeptides, and proteinases or endopeptidases, which are capable of cleaving peptide bonds in the central regions of polypeptides. The endopeptidases are classified in
-
A novel series of DHODH inhibitors was developed
2019-09-02
A novel series of DHODH inhibitors was developed by us based on a lead that was discovered during a docking procedure and medicinal chemistry exploration. The activity of the initial lead was improved by a QSAR method and yielded low nanomolar inhibitors. Introduction The most common metabolic h
-
Cysteine protease inhibitors representing several chemical s
2019-09-02
Cysteine protease inhibitors representing several chemical scaffold types are effective in halting parasite replication without toxicity to the host (Renslo and McKerrow, 2006). A vinyl sulfone cysteine protease inhibitor, K11777, is completing final Good Laboratory Practice (GLP) preclinical tests
-
br Preparation of Recombinant Proteins br Activity Assays
2019-09-02
Preparation of Recombinant Proteins Activity Assays The following solvents are used in the procedures described in this section: Data Analysis Aryl radical rearrangements typically result in a large number of products being generated by Bmp7. Approaches combining mass spectrometry and NMR
-
Our primary research question is that
2019-09-02
Our primary research question is that of the comparative efficacy of accelerated and traditional accounting programs as manifest by success on the CPA exam. We recognize that due to a number of personal and career decisions, not all of those qualified from any of our programs will attempt the CPA ex
-
O6-Benzylguanine kinase These data indicate that in the cont
2019-09-02
These data indicate that, in the context of the N-terminal 42 amino acids of p53, threonine 18 is a substrate for phosphorylation by CK1 as mediated by prior phosphorylation of serine 15. To determine whether this is a property of full length p53, GST-p53 fusion proteins comprising the full length p
-
iib iiia inhibitors br Conflict statement br Introduction Pr
2019-08-30
Conflict statement Introduction Prostate cancer (PCa) is the second most frequently diagnosed cancer and the second leading cause of cancer death in men after lung cancer [1], [2]. The incidence and mortality rate of prostate cancer are significantly higher in developed countries especially th
-
dna methyltransferase Today many strategies have been develo
2019-08-30
Today, many strategies have been developed to enhance CXCR-4 receptor dna methyltransferase on the cell surface, either by modifying the cell culture medium or by modifying the CXCR-4 gene in BMSCs to stimulate stem cell recruitment (Jiang et al., 2012, Liu et al., 2014b). For instance, the pre-con
-
Table gives the list of components which will
2019-08-30
Table 1 gives the list of components which will be modeled. Transient Voltage Suppressor (TVS) as well as passive elements will be also modeled. For each component, we will choose the EMC (emission and immunity) and transient immunity measurement method adapted to extract the component model. A com
-
br Management of Hypertension The aim of
2019-08-30
Management of Hypertension The aim of treating HT is to reduce the risk of adverse cardiovascular outcomes: mainly coronary artery disease, stroke, and death. For this reason, the decision whether to initiate pharmacological treatment or not will depend not only on BP values, but also on the over
-
br Introduction Epithelial mesenchymal transition
2019-08-30
Introduction Epithelial-mesenchymal transition (EMT) is a biological process by which epithelial Vincristine sulfate lose cell polarity and cell-cell adhesion, and gain mesenchymal features with an increase of migratory and invasive properties [1]. EMT is essential for mesoderm formation during
-
MI has been detected in wastewater at concentrations
2019-08-30
3MI has been detected in wastewater at concentrations of 640–700 μg L−1 (Hwang et al., 1995) and up to 20 mg L−1 in decaying algal water environments (Peller et al., 2014). It is likely that 3MI accumulation in fish might be due to the degradation of endogenous amino acids. The presence of this che
-
As small non coding RNAs microRNAs
2019-08-30
As small non-coding RNAs, microRNAs (miRNAs) can control gene expression at the post-transcriptional level by binding to the 3′-untranslated regions (3′-UTR) of messenger RNAs (mRNA) [15], [16]. miRNAs have been anticipated to regulate virtually all cellular mechanisms [17] and to play an important
-
AMPHs facilitate dopamine release which further
2019-08-30
AMPHs facilitate dopamine release, which further triggers dopamine depletion [72]. Indeed, we observed that repeated treatment of MPA significantly inhibited TH-, DAT-, and VMAT-2 levels. Since DAT and VMAT-2 are important for dopaminergic terminal markers [10], their decreases suggest that MPA-indu
-
Although there was little to no expression
2019-08-30
Although there was little to no expression change observed by TELI of the recA and ruvA genes upon CAA exposure, other specific repair pathways were induced by both CAA and SO and include the SOS-inducible gene sulA, the DNA repair gene ykfG, the mismatch repair gene mutS, the recombination and repa
15027 records 974/1002 page Previous Next First page 上5页 971972973974975 下5页 Last page